# Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

> **NCT03140943** · PHASE2 · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 100 (estimated)

## Conditions studied

- Relapsed and/or Refractory Multiple Myeloma

## Interventions

- **DRUG:** Carfilzomib, Thalidomide and Dexamethasone

## Key facts

- **NCT ID:** NCT03140943
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-09-13
- **Primary completion:** 2019-06-01
- **Final completion:** 2022-06-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2017-11-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03140943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03140943, "Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03140943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*